ProfileGDS5678 / 1444421_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 44% 44% 45% 40% 48% 47% 40% 49% 40% 44% 44% 42% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0664644
GSM967853U87-EV human glioblastoma xenograft - Control 23.0189144
GSM967854U87-EV human glioblastoma xenograft - Control 33.0221244
GSM967855U87-EV human glioblastoma xenograft - Control 42.9991745
GSM967856U87-EV human glioblastoma xenograft - Control 52.8733140
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2190948
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.178347
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9191440
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1387449
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8973840
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0044444
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9972744
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9857142
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9988843